Evidence map›Paper›PMID 38570473›Full record

Trial reportChinese journal of integrative medicine2024

Naoxueshu Oral Liquid Accelerates Post-Craniotomy Hematoma Absorption in Patients: An Open-Label, Multicenter, and Randomized Controlled Trial.

Qiu He, Fu-Xin Lin, Jin-Ye Su, Ling-Yun Zhuo, Qing Zhu, Xiao-Chuan Sun, Rong-Cai Jiang, Zhi-Gang Yao, Lei Wang, Yan-Wei Dang and 8 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Chinese journal of integrative medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 11 institutions in 1 country.

Qiu HeDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Fu-Xin LinDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Jin-Ye SuDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Ling-Yun ZhuoDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Qing ZhuDepartment of Neurosurgery, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, 215000, China.
Xiao-Chuan SunDepartment of Neurosurgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400000, China.
Rong-Cai JiangDepartment of Neurosurgery, Tianjin Medical University General Hospital, Tianjin, 300000, China.
Zhi-Gang YaoDepartment of Neurosurgery, The Third Hospital of Shijiazhuang, Shijiazhuang, 050000, China.
Lei WangDepartment of Neurosurgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, Hubei Province, 443000, China.
Yan-Wei DangDepartment of Neurosurgery, Xiangyang No. 1 People's Hospital Affiliated to Hubei University of Medicine, Xiangfan, Hubei Province, 441100, China.
De-Zhong LiuDepartment of Neurosurgery, Zhoukou Central Hospital, Zhoukou, Henan Province, 466000, China.
Yang LiuDepartment of Neurosurgery, The Third Hospital of Mianyang, Mianyang, Sichuan Province, 621000, China.
Wen-Hua FangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Fang-Yu WangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
Yuan-Xiang LinDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
An-Xin WangDepartment of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100000, China.
Deng-Liang WangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China.
De-Zhi KangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350004, China. kdz99988@vip.sina.com.
First Affiliated Hospital of Fujian Medical University · CNFujian Medical University · CNBeijing Municipal Engineering Design and Research Institute (China) · CNChina Three Gorges University · CNFirst Affiliated Hospital of Chongqing Medical University · CNFirst Hospital of Shijiazhuang · CNHubei University of Medicine · CNMianyang Third People's Hospital · CNSecond Affiliated Hospital of Soochow University · CNTianjin Medical University General Hospital · CNZhoukou City Academy of Agricultural Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo investigate whether Naoxueshu Oral Liquid (NXS) could promote hematoma absorption in post-craniotomy hematoma (PCH) patients.

methodsThis is an open-label, multicenter, and randomized controlled trial conducted at 9 hospitals in China. Patients aged 18-80 years with post-craniotomy supratentorial hematoma volume ranging from 10 to 30 mL or post-craniotomy infratentorial hematoma volume less than 10 mL, or intraventricular hemorrhage following cranial surgery were enrolled. They were randomly assigned at a 1:1 ratio to the NXS (10 mL thrice daily for 15 days) or control groups using a randomization code table. Standard medical care was administered in both groups. The primary outcome was the percentage reduction in hematoma volume from day 1 to day 15. The secondary outcomes included the percentage reduction in hematoma volume from day 1 to day 7, the absolute reduction in hematoma volume from day 1 to day 7 and 15, and the change in neurological function from day 1 to day 7 and 15. The safety was closely monitored throughout the study. Moreover, subgroup analysis was performed based on age, gender, history of diabetes, and etiology of intracerebral hemorrhage (ICH).

resultsA total of 120 patients were enrolled and randomly assigned between March 30, 2018 and April 15, 2020. One patient was lost to follow-up in the control group. Finally, there were 119 patients (60 in the NXS group and 59 in the control group) included in the analysis. In the full analysis set (FAS) analysis, the NXS group had a greater percentage reduction in hematoma volume from day 1 to day 15 than the control group [median (Q1, Q3): 85% (71%, 97%) vs. 76% (53%, 93%), P<0.05]. The secondary outcomes showed no statistical significance between two groups, either in FAS or per-protocol set (P>0.05). Furthermore, no adverse events were reported during the study. In the FAS analysis, the NXS group exhibited a higher percentage reduction in hematoma volume on day 15 in the following subgroups: male patients, patients younger than 65 years, patients without diabetes, or those with initial cranial surgery due to ICH (all P<0.05).

conclusionsThe administration of NXS demonstrated the potential to promote the percentage reduction in hematoma volume from day 1 to day 15. This intervention was found to be safe and feasible. The response to NXS may be influenced by patient characteristics. (Registration No. ChiCTR1800017981).

Indexed as

CraniotomyDrugs, Chinese HerbalHematomaAdministration, OralAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultDrugs, Chinese HerbalChinese medicinehematoma absorptionNaoxueshu Oral Liquidpost-craniotomy hematomarandomized controlled trial

Identifiers

PMID38570473
OpenAlexW4393945008

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.